文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症心脑血管急症

分子靶向治疗相关危及生命的毒性:已发表病例的系统评价

Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases.
PubMed 文献 · Intensive Care Med · 2019-05-29
一句话结论分子靶向治疗相关危重毒性以抗血管生成药(40.3%)和免疫检查点抑制剂(33.6%)为主,多表现为胃肠道与心血管并发症,需早期识别。

该研究对PubMed截至2019年3月收录的、因分子靶向治疗相关危及生命毒性入住ICU的病例报告进行了系统评价,最终纳入253例。其中40.3%(n=102)与抗血管生成药物相关,主要表现为胃肠道和心血管并发症;33.6%(n=85)与免疫检查点抑制剂相关,13.0%(n=33)与EGFR抑制剂相关,4.0%(n=10)与抗HER2药物相关。研究指出,相较于接受治疗的患者总数,严重毒性报道仅253例,症状和生物标志物需进一步明确以改善报告和治疗剂量与方案的调整。

要点

  • 因分子靶向治疗危重毒性入ICU的253例报告中,抗血管生成药占40.3%(n=102),主要为胃肠道和心血管并发症。
  • 免疫检查点抑制剂相关危重毒性占33.6%(n=85),EGFR抑制剂占13.0%(n=33),抗HER2药物占4.0%(n=10)。
  • 免疫检查点抑制剂、EGFR抑制剂和抗HER2药物相关的危重不良事件包括呼吸系统或超敏反应事件。
  • 作者认为需更好地识别描绘这些事件的症状和生物标志物,以利于恰当报告并调整治疗剂量和方案。

适用人群与场景

  • 因分子靶向治疗相关危及生命毒性入住ICU的恶性肿瘤患者。
  • 仅纳入FDA批准的分子靶向治疗药物相关病例;未纳入非FDA批准的联合方案或激素治疗。

红旗征与不能漏的情况

  • 抗血管生成药物相关危重毒性主要表现为胃肠道和心血管并发症。
  • 免疫检查点抑制剂、EGFR抑制剂和抗HER2药物相关危重毒性可表现为呼吸系统或超敏反应事件。

研究设计与关键结果

  • 系统评价纳入253例因分子靶向治疗相关危及生命毒性入住ICU的已发表病例报告。
  • 40.3%(n=102)与抗血管生成药物相关,主要为胃肠道和心血管并发症。
  • 33.6%(n=85)与免疫检查点抑制剂相关,13.0%(n=33)与EGFR抑制剂相关,4.0%(n=10)与抗HER2药物相关。
  • 免疫检查点抑制剂、EGFR抑制剂和抗HER2药物相关的危重不良事件包括呼吸系统或超敏反应事件。

证据类型、等级与局限

  • 证据类型:已发表病例报告的系统评价。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为需更好地识别描绘分子靶向治疗危重毒性的症状和生物标志物,以利于恰当报告并调整治疗剂量和方案。
  • 基于接受治疗的患者总数,仅253例分子靶向治疗相关严重毒性被报告。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Molecular targeted therapy increased overall and disease-free survival in a wide range of malignancies. Although generally well tolerated compared to chemotherapy, molecular targeted therapy may be associated with adverse events requiring ICU admission. Informing clinicians about clinical features of these toxic events might maintain awareness and favor early recognition, prompt diagnosis and treatment.

METHODS: We performed a systematic review of published case reports of molecular targeted therapy-related life-threatening toxicity that led to ICU admission. The search used the Pubmed database using medical subject heading (Mesh) terms, including all FDA-approved molecular targeted therapy (TT), up to March 2019. No language restriction was applied. All cases reports of patients admitted to the ICU for molecular targeted therapy-related toxicity were included. Non-FDA-approved combinations of treatments or hormonal therapy were not included.

RESULTS: Two hundred and fifty-three cases were identified. Nearly half of them (n = 102; 40.3%) were related to anti-angiogenic agents, mostly for gastrointestinal and cardiovascular complications. Other molecules responsible for adverse events were chiefly immune checkpoint inhibitors (n = 85, 33.6%), EGFR inhibitors (n = 33; 13.0%), and anti-HER2 (n = 10; 4.0%). They were associated with adverse events such as respiratory or hypersensitivity events. Management and outcomes associated with these life-threatening complications are reported.

CONCLUSIONS: Based on the vast number of treated patients, only 253 cases of molecular therapy-related severe toxicity are reported in cancer patients. Symptoms and biomarkers that depict these events need to be better identified as to allow appropriate reporting and improving dose and schedule of the treatment adapted to each patient.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Assoun S, Lemiale V, Azoulay E, et al. Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases. Intensive Care Med. 2019. PMID: 31143997. doi:10.1007/s00134-019-05650-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。